ReviewRadiation oncology (London, England)2026
Breast cancer radiotherapy in patients with autoimmune or cancer-associated myositis: balancing oncological benefit and immune-mediated risk.
Review in Radiation oncology (London, England), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer radiotherapy and autoimmune myositis intersect in a clinically complex setting in which paraneoplastic disease, pre-existing inflammatory myopathy, and radiation-related muscle injury may overlap. Dermatomyositis is the idiopathic inflammatory myopathy most strongly associated with malignancy, and breast cancer is one of the solid tumours most frequently reported in cancer-associated myositis, particularly in anti-TIF1γ- and anti-NXP2-positive subsets.
methodsA structured narrative review of PubMed and Scopus was performed from database inception to March 2026. Evidence was synthesised qualitatively owing to limited and heterogeneous literature.
resultsMuscle symptoms during breast cancer treatment may reflect autoimmune, paraneoplastic, radiation-induced, fibrosis-related, or recall myositis. MRI is the most informative modality for pattern-based assessment, with FDG PET-CT and ultrasound providing complementary value in selected cases. Although direct disease-specific evidence is sparse and derives largely from retrospective series, mixed connective tissue disease cohorts, radiobiological studies, and case reports, radiotherapy does not appear to represent an automatic contraindication when disease activity, multidisciplinary evaluation, and conformal planning are taken into account.
conclusionsBreast cancer radiotherapy in patients with autoimmune or cancer-associated myositis requires structured differential diagnosis rather than categorical avoidance. Diagnostic assessment should integrate timing, field distribution, imaging, serology, systemic features, and treatment sequence. Further studies should refine risk stratification, muscle-specific dose constraints, and biomarkers distinguishing radiation-related from autoimmune or paraneoplastic myositis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.